APhA urges FDA to put patient safety first in review of peptide substances

Summary

The American Pharmacists Association is urging the FDA and Pharmacy Compounding Advisory Committee to prioritize patient safety and scientific evidence in reviewing unregulated peptide substances as the market for these products continues to expand.